Investigation Of Bglsp's Mechanisms In Ulcer Healing:Network Pharmacology

To investigate the therapeutic potential and mechanism of wall-broken Ganoderma lucidum spore powder (BGLSP) in cutaneous ulcer healing. Cutaneous ulcers were induced in C3H mice (n=6/group): untreated controls, recombinant bovine fibroblast growth factor (rbFGF-b)-treated controls, and BGLSP-treated group. Daily topical applications were performed for 9 days, with photometric assessment every 48 hours to calculate healing rates. Histopathological evaluation (hematoxylin-eosin and Masson staining) . LC-MS-based component screening were conducted. Network pharmacology identified ulcer-related targets from GeneCards/OMIM/TTD and compound targets from Swiss Target Prediction/TCMSP. Venn analysis identified overlapping targets for PPI network construction (STRING), functional enrichment (DAVID), and pathway mapping (Cytoscape). Molecular docking (AutoDock Vina) validated ligand-target interactions. BGLSP significantly enhanced ulcer healing, comparable to rbFGF-b. Histology confirmed accelerated collagen deposition and re-epithelialization in BGLSP-treated ulcers. LC-MS identified ganoderic acid, ganoderdiol, and other components as bioactive constituents.Network pharmacology revealed 158 overlapping targets, including TNF, AKT1, IL1B, and EGFR. Molecular docking confirmed strong binding between active compounds and targets. Pathway enrichment demonstrated coordinated regulation of PI3K/AKT, TNF, and IL-17 signaling. This study, employing animal experiments, LC-MS, and network pharmacology, revealed that BGLSP promotes ulcer healing through multi-target and multi-pathway mechanisms.